An early humoral immune response in peripheral blood following parenteral inactivated influenza vaccination. 1994

R J Cox, and K A Brokstad, and M A Zuckerman, and J M Wood, and L R Haaheim, and J S Oxford
Department of Medical Microbiology, London Hospital Medical College, Whitechapel, UK.

The enzyme-linked immunospot assay was used to examine the humoral immune response in 15 healthy volunteers immunized with either split or subunit inactivated trivalent influenza vaccine containing A/Beijing/353/89 (H3N2), A/Taiwan/1/86 (H1N1) and B/Yamagata/16/88. The rapidity of the individual B-cell and serum antibody response was examined in lymphocyte and serum samples collected at various time intervals after vaccination. A rapid serological response was detected with increases in antibody titre detected in the majority of volunteers by 7-8 days postvaccination. Influenza-specific plasma cells were detected as early as 4 days postvaccination, higher numbers of IgA and IgG antibody-secreting cells (ASC) were observed which peaked at 7-8 days postvaccination. The number of ASCs then declined, with low numbers of cells detected at 11 days postvaccination. Influenza-specific IgA ASCs were predominantly of the IgA1 subclass. This rapid immune response may have a bearing on future vaccination policies of unimmunized 'at risk groups' in times of high influenza activity.

UI MeSH Term Description Entries
D007132 Immunoglobulin Isotypes The classes of immunoglobulins found in any species of animal. In man there are nine classes that migrate in five different groups in electrophoresis; they each consist of two light and two heavy protein chains, and each group has distinguishing structural and functional properties. Antibody Class,Ig Isotype,Ig Isotypes,Immunoglobulin Class,Immunoglobulin Isotype,Antibody Classes,Immunoglobulin Classes,Class, Antibody,Class, Immunoglobulin,Classes, Antibody,Classes, Immunoglobulin,Isotype, Ig,Isotype, Immunoglobulin,Isotypes, Ig,Isotypes, Immunoglobulin
D007252 Influenza Vaccines Vaccines used to prevent infection by viruses in the family ORTHOMYXOVIRIDAE. It includes both killed and attenuated vaccines. The composition of the vaccines is changed each year in response to antigenic shifts and changes in prevalence of influenza virus strains. The flu vaccines may be mono- or multi-valent, which contains one or more ALPHAINFLUENZAVIRUS and BETAINFLUENZAVIRUS strains. Flu Vaccine,Influenzavirus Vaccine,Monovalent Influenza Vaccine,Universal Flu Vaccine,Universal Influenza Vaccine,Flu Vaccines,High-Dose Trivalent Influenza Vaccine,Influenza Vaccine,Influenza Virus Vaccine,Influenza Virus Vaccines,Influenzavirus Vaccines,Intranasal Live-Attenuated Influenza Vaccine,LAIV Vaccine,Monovalent Influenza Vaccines,Quadrivalent Influenza Vaccine,Trivalent Influenza Vaccine,Trivalent Live Attenuated Influenza Vaccine,Universal Flu Vaccines,Universal Influenza Vaccines,Flu Vaccine, Universal,High Dose Trivalent Influenza Vaccine,Influenza Vaccine, Monovalent,Influenza Vaccine, Quadrivalent,Influenza Vaccine, Trivalent,Influenza Vaccine, Universal,Intranasal Live Attenuated Influenza Vaccine,Vaccine, Flu,Vaccine, Influenza,Vaccine, Influenza Virus,Vaccine, Influenzavirus,Vaccine, LAIV,Vaccine, Monovalent Influenza,Vaccine, Quadrivalent Influenza,Vaccine, Trivalent Influenza,Virus Vaccine, Influenza
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009500 Neutralization Tests The measurement of infection-blocking titer of ANTISERA by testing a series of dilutions for a given virus-antiserum interaction end-point, which is generally the dilution at which tissue cultures inoculated with the serum-virus mixtures demonstrate cytopathology (CPE) or the dilution at which 50% of test animals injected with serum-virus mixtures show infectivity (ID50) or die (LD50). Neutralization Test,Test, Neutralization,Tests, Neutralization
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D005260 Female Females
D006385 Hemagglutination Inhibition Tests Serologic tests in which a known quantity of antigen is added to the serum prior to the addition of a red cell suspension. Reaction result is expressed as the smallest amount of antigen which causes complete inhibition of hemagglutination. Hemagglutination Inhibition Test,Inhibition Test, Hemagglutination,Inhibition Tests, Hemagglutination,Test, Hemagglutination Inhibition,Tests, Hemagglutination Inhibition
D006462 Hemolytic Plaque Technique A method to identify and enumerate cells that are synthesizing ANTIBODIES against ANTIGENS or HAPTENS conjugated to sheep RED BLOOD CELLS. The sheep red blood cells surrounding cells secreting antibody are lysed by added COMPLEMENT producing a clear zone of HEMOLYSIS. (From Illustrated Dictionary of Immunology, 3rd ed) Jerne's Plaque Technique,Hemolytic Plaque Technic,Jerne's Plaque Technic,Hemolytic Plaque Technics,Hemolytic Plaque Techniques,Jerne Plaque Technic,Jerne Plaque Technique,Jernes Plaque Technic,Jernes Plaque Technique,Plaque Technic, Hemolytic,Plaque Technic, Jerne's,Plaque Technics, Hemolytic,Plaque Technique, Hemolytic,Plaque Technique, Jerne's,Plaque Techniques, Hemolytic,Technic, Hemolytic Plaque,Technic, Jerne's Plaque,Technics, Hemolytic Plaque,Technique, Hemolytic Plaque,Technique, Jerne's Plaque,Techniques, Hemolytic Plaque
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man

Related Publications

R J Cox, and K A Brokstad, and M A Zuckerman, and J M Wood, and L R Haaheim, and J S Oxford
July 2023, Vaccine,
R J Cox, and K A Brokstad, and M A Zuckerman, and J M Wood, and L R Haaheim, and J S Oxford
January 2023, Frontiers in public health,
R J Cox, and K A Brokstad, and M A Zuckerman, and J M Wood, and L R Haaheim, and J S Oxford
March 1973, Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B,
R J Cox, and K A Brokstad, and M A Zuckerman, and J M Wood, and L R Haaheim, and J S Oxford
March 1982, American journal of veterinary research,
R J Cox, and K A Brokstad, and M A Zuckerman, and J M Wood, and L R Haaheim, and J S Oxford
December 2001, The European respiratory journal,
R J Cox, and K A Brokstad, and M A Zuckerman, and J M Wood, and L R Haaheim, and J S Oxford
April 1986, Zentralblatt fur Veterinarmedizin. Reihe B. Journal of veterinary medicine. Series B,
R J Cox, and K A Brokstad, and M A Zuckerman, and J M Wood, and L R Haaheim, and J S Oxford
April 1975, Infusionstherapie und klinische Ernahrung,
R J Cox, and K A Brokstad, and M A Zuckerman, and J M Wood, and L R Haaheim, and J S Oxford
April 2011, The Journal of infectious diseases,
R J Cox, and K A Brokstad, and M A Zuckerman, and J M Wood, and L R Haaheim, and J S Oxford
January 2024, Journal of immunology (Baltimore, Md. : 1950),
R J Cox, and K A Brokstad, and M A Zuckerman, and J M Wood, and L R Haaheim, and J S Oxford
December 1993, Aging (Milan, Italy),
Copied contents to your clipboard!